FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220656413> ?p ?o ?g. }

• W4220656413 abstract "Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Methods We searched the PUBMED, Embase and Cochrane databases for relevant studies published up until 10 December 2021. Cardiovascular and renal outcome trials reporting outcomes on GLP-1RA, SGLT-2 inhibitors and DPP-4 inhibitors in patients with or without type 2 diabetes mellitus were included. The primary outcome was major adverse cardiovascular events (MACE); other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome. Results Twenty-three trials enrolling a total number of 181,143 participants were included. DPP-4 inhibitors did not lower the risk of any cardiorenal outcome when compared with placebo and were associated with higher risks of MACE, HHF, and renal outcome when compared with the other two drug classes. SGLT-2 inhibitors significantly reduced cardiovascular (RR = 0.88) and total (RR = 0.87) death, as compared with DPP-4 inhibitors, while GLP-1 RA reduced total death only (RR = 0.87). The comparison between GLP-1RA and SGLT-2 inhibitors showed no difference in their risks of MACE, nonfatal MI, nonfatal stroke, CV and total death; SGLT-2 inhibitors were superior to GLP-1RA in reducing the risk of HHF and the renal outcome (24% and 22% lower risk, respectively). Only GLP-1RA reduced the risk of nonfatal stroke (RR = 0.84), as compared with placebo. There was no head-to-head trial directly comparing these antidiabetic drug classes. Conclusions SGLT-2 inhibitors and GLP-1RA are superior to DPP-4 inhibitors in reducing the risk of most cardiorenal outcomes; SGLT-2 inhibitors are superior to GLP-1RA in reducing the risk of HHF and renal events; GLP-1RA only reduced the risk of nonfatal stroke. Both SGLT-2 inhibitors and GLP-1RA should be the preferred treatment for type 2 diabetes and cardiorenal diseases." @default.
• W4220656413 created "2022-04-03" @default.
• W4220656413 creator A5005815956 @default.
• W4220656413 creator A5027200822 @default.
• W4220656413 creator A5043443418 @default.
• W4220656413 creator A5048229494 @default.
• W4220656413 creator A5052044111 @default.
• W4220656413 creator A5054314823 @default.
• W4220656413 creator A5056173815 @default.
• W4220656413 date "2022-03-16" @default.
• W4220656413 modified "2023-10-13" @default.
• W4220656413 title "The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs" @default.
• W4220656413 cites W2012932483 @default.
• W4220656413 cites W2082960515 @default.
• W4220656413 cites W2098923148 @default.
• W4220656413 cites W2111999709 @default.
• W4220656413 cites W2150529573 @default.
• W4220656413 cites W2150561315 @default.
• W4220656413 cites W2150959326 @default.
• W4220656413 cites W2157823046 @default.
• W4220656413 cites W2588681363 @default.
• W4220656413 cites W2806521060 @default.
• W4220656413 cites W2902527999 @default.
• W4220656413 cites W2971147579 @default.
• W4220656413 cites W2995560091 @default.
• W4220656413 cites W3003299879 @default.
• W4220656413 cites W3010343201 @default.
• W4220656413 cites W3022903699 @default.
• W4220656413 cites W3096486083 @default.
• W4220656413 cites W3099387352 @default.
• W4220656413 cites W3131557571 @default.
• W4220656413 cites W3173421961 @default.
• W4220656413 cites W3199651111 @default.
• W4220656413 cites W3200330589 @default.
• W4220656413 cites W3200446817 @default.
• W4220656413 cites W3205244879 @default.
• W4220656413 cites W3207079769 @default.
• W4220656413 cites W3213339196 @default.
• W4220656413 cites W4200089918 @default.
• W4220656413 cites W4200439235 @default.
• W4220656413 doi "https://doi.org/10.1186/s12933-022-01474-z" @default.
• W4220656413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35296336" @default.
• W4220656413 hasPublicationYear "2022" @default.
• W4220656413 type Work @default.
• W4220656413 citedByCount "44" @default.
• W4220656413 countsByYear W42206564132022 @default.
• W4220656413 countsByYear W42206564132023 @default.
• W4220656413 crossrefType "journal-article" @default.
• W4220656413 hasAuthorship W4220656413A5005815956 @default.
• W4220656413 hasAuthorship W4220656413A5027200822 @default.
• W4220656413 hasAuthorship W4220656413A5043443418 @default.
• W4220656413 hasAuthorship W4220656413A5048229494 @default.
• W4220656413 hasAuthorship W4220656413A5052044111 @default.
• W4220656413 hasAuthorship W4220656413A5054314823 @default.
• W4220656413 hasAuthorship W4220656413A5056173815 @default.
• W4220656413 hasBestOaLocation W42206564131 @default.
• W4220656413 hasConcept C126322002 @default.
• W4220656413 hasConcept C127413603 @default.
• W4220656413 hasConcept C134018914 @default.
• W4220656413 hasConcept C156490143 @default.
• W4220656413 hasConcept C164705383 @default.
• W4220656413 hasConcept C170493617 @default.
• W4220656413 hasConcept C185280430 @default.
• W4220656413 hasConcept C2776442814 @default.
• W4220656413 hasConcept C2777180221 @default.
• W4220656413 hasConcept C2778198053 @default.
• W4220656413 hasConcept C2778938600 @default.
• W4220656413 hasConcept C2779284873 @default.
• W4220656413 hasConcept C2780400711 @default.
• W4220656413 hasConcept C2780533449 @default.
• W4220656413 hasConcept C2780645631 @default.
• W4220656413 hasConcept C2780739214 @default.
• W4220656413 hasConcept C500558357 @default.
• W4220656413 hasConcept C555293320 @default.
• W4220656413 hasConcept C71924100 @default.
• W4220656413 hasConcept C78519656 @default.
• W4220656413 hasConcept C95190672 @default.
• W4220656413 hasConceptScore W4220656413C126322002 @default.
• W4220656413 hasConceptScore W4220656413C127413603 @default.
• W4220656413 hasConceptScore W4220656413C134018914 @default.
• W4220656413 hasConceptScore W4220656413C156490143 @default.
• W4220656413 hasConceptScore W4220656413C164705383 @default.
• W4220656413 hasConceptScore W4220656413C170493617 @default.
• W4220656413 hasConceptScore W4220656413C185280430 @default.
• W4220656413 hasConceptScore W4220656413C2776442814 @default.
• W4220656413 hasConceptScore W4220656413C2777180221 @default.
• W4220656413 hasConceptScore W4220656413C2778198053 @default.
• W4220656413 hasConceptScore W4220656413C2778938600 @default.
• W4220656413 hasConceptScore W4220656413C2779284873 @default.
• W4220656413 hasConceptScore W4220656413C2780400711 @default.
• W4220656413 hasConceptScore W4220656413C2780533449 @default.
• W4220656413 hasConceptScore W4220656413C2780645631 @default.
• W4220656413 hasConceptScore W4220656413C2780739214 @default.
• W4220656413 hasConceptScore W4220656413C500558357 @default.
• W4220656413 hasConceptScore W4220656413C555293320 @default.
• W4220656413 hasConceptScore W4220656413C71924100 @default.
• W4220656413 hasConceptScore W4220656413C78519656 @default.
• W4220656413 hasConceptScore W4220656413C95190672 @default.
• W4220656413 hasIssue "1" @default.
• W4220656413 hasLocation W42206564131 @default.

• next